Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
56.26
-0.07 (-0.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Why Novavax Stock More Than Doubled Today
May 10, 2024
A cloud of doubt hanging over the company just gave way to some sunshine.
Via
The Motley Fool
NVAX Stock Alert: Novavax Just Hit a New 52-Week High
May 10, 2024
Novavax stock is heading higher on Friday as NVAX investors celebrate it reaching a new 52-week high following a deal with Sanofi.
Via
InvestorPlace
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
May 10, 2024
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Novavax Sheds Going Concern Warning as NVAX Stock Pops on Sanofi Licensing Deal
May 10, 2024
NVAX stock is rising higher after the biotechnology company announced that it had signed a licensing deal with Sanofi.
Via
InvestorPlace
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Biotech Rockets 125% On Sanofi Covid Vaccine Agreement
May 10, 2024
Novavax will receive as much as $1.2 billion as part of a Covid vaccine licensing deal with Sanofi.
Via
Investor's Business Daily
Exposures
COVID-19
Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern
May 10, 2024
Novavax strikes co-exclusive licensing deal with Sanofi (SNY) for COVID-19 and flu-COVID-19 vaccines. Terms include upfront payment of $500M, milestone opportunities, and revenue guidance update.
Via
Benzinga
Exposures
COVID-19
Why Is Novavax (NVAX) Stock Up 118% Today?
May 10, 2024
Novavax stock is up on Friday after the vaccine company announced a licensing agreement with Sanofi as its Q1 earnings report.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 10, 2024
The biggest pre-market stock movers are ready to go as we check out all of the hottest news happening on Friday morning!
Via
InvestorPlace
3 Biotech Stocks to Sell in May Before They Crash & Burn
May 10, 2024
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.
Via
InvestorPlace
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
May 09, 2024
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks.
Via
InvestorPlace
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
May 08, 2024
Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Sanofi's New Cancer Drug Could Help Deliver a Big Payday
May 08, 2024
Investors should expect a modest 2024 before seeing more exciting returns for the drugmaker in 2025 following the expected approval of rilzabrutinib.
Via
The Motley Fool
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
May 02, 2024
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.
Via
Benzinga
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 02, 2024
It pays to develop novel medicines for life-threatening illnesses.
Via
The Motley Fool
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024
April 30, 2024
From
Pinnacle Group International
Via
ACN Newswire
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
April 28, 2024
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for...
Via
Talk Markets
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
April 25, 2024
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.
Via
Benzinga
Sanofi (SNY) Q1 2024 Earnings Call Transcript
April 25, 2024
SNY earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
April 25, 2024
Via
Benzinga
Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
April 25, 2024
Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to...
Via
Benzinga
SNY Stock Earnings: Sanofi Beats EPS, Beats Revenue for Q1 2024
April 25, 2024
SNY stock results show that Sanofi beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
April 25, 2024
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.
Via
Investor's Business Daily
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...
Via
Benzinga
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
April 25, 2024
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META)
Via
Benzinga
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
April 17, 2024
Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed.
Via
Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity
April 17, 2024
Discover results from Sanofi's Phase 2 study on frexalimab for relapsing multiple sclerosis. Explore sustained reduction in disease activity and lesion numbers with low relapse rates.
Via
Benzinga
Novo Nordisk Arms Wegovy to Be a Triple Threat
April 15, 2024
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders
Via
MarketBeat
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
April 12, 2024
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.